Mycobacterium avium Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mycobacterium avium Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Mycobacterium avium Infections is the most common cause of nontuberculosis mycobacterial species infections in humans, and the respiratory system is the most common site of infection. It consists of multiple nontuberculosis mycobacterial species (NTM). It is considered an opportunistic infection most observed in immunocompromised ones. It is caused by a group of bacteria most common species is M. avium and its sub-species. The mode of infection is inhalational route, ingestion through gastrointestinal. Commonly seen in those with low CD4 count, HIV patients, and a risk factor in respiratory infections like pneumonia, TB, and COPD. Symptoms range from one individual to another from chronic cough, cold, chills and fever, and hemoptysis. Diagnosis is done by CT scan and chest X-ray. Antibiotics are primary medicines targeted in MAV patients followed by symptomatic treatment. Common antibiotics are macrolides, anti-TB drugs rifampicin, ethambutol, aminoglycosides, etc. Combination therapy in severe conditions.
The Mycobacterium avium Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Mycobacterium avium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mycobacterium avium Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mycobacterium avium Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mycobacterium avium Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mycobacterium avium Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mycobacterium avium Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AGILeBiotics BVAN2 Therapeutics Inc
Brii Biosciences Ltd
Crestone Inc
Eli Lilly and Co
HAV Vaccines Ltd
Insmed Inc
OP BIO FACTORY Co Ltd
RevImmune SAS
SciBac Inc
Spero Therapeutics Inc
University of Mississippi
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Mycobacterium avium Infections reports